The block of the binding of PD-1 and its ligands has the potential to make tumor cells exposure to the immune regulatory activity of effector T cells and resume an effective antitumor immune response (Figure 4) (Sharpe and Freeman, 2002; Francisco et al., 2010; Pardoll, 2012). This evidence concerns the gene PDCD1 and neoplasm.